Page last updated: 2024-10-20

pyridine and Neoplasms

pyridine has been researched along with Neoplasms in 22 studies

azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"The incidence of cancer is increasing worldwide, affecting a vast majority of the human population, therefore, new different anticancer agents are being developed now and their safety still needs to be evaluated."2.82Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer. ( Kumar, A; Kumar, R; Majee, C; Mazumder, A; Mishra, R; Sahu, R, 2022)
" Since compound 1k displayed favorable bioavailability in mouse cassette dosing PK study, we conducted in vivo Pharmacodynamics (PD) studies of this compound."1.51Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor. ( Asano, M; Maezaki, H; Mizojiri, R; Nii, N; Sasaki, M; Satoh, Y; Sumi, H; Yamamoto, Y, 2019)
"ten times more cytotoxic against breast cancer (4T1) and human lung adenocarcinoma epithelial cells (A549) than a well-known anticancer drug, cisplatin."1.42The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells. ( Brindell, M; Kieda, C; Mazuryk, O; Suzenet, F, 2015)
"In particular, in colorectal cancer cells, expression of the cancer suppressor genes APC and p53 was increased following exposure to 6."1.40Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls. ( Chi, KW; Jeong, YJ; Jo, JH; Kang, SC; Lah, MS; Mishra, A, 2014)
"Compound 1 itself displays anticancer activity in HeLa, HepG2 and Jurkat cells with an enhancement on addition of the metal ions."1.37Impact of metal binding on the antitumor activity and cellular imaging of a metal chelator cationic imidazopyridine derivative. ( Chakravarthi, BV; Chakravarty, AR; Jayabaskaran, C; Karande, AA; Roy, M, 2011)
" Tumor growth inhibition was observed during the dosing interval, and the tumors regrew when compound administration was ceased."1.33Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. ( Bouska, JJ; de Jong, R; Giranda, VL; Gramling-Evans, EE; Guan, R; Han, EK; Johnson, EF; Klinghofer, V; Leverson, JD; Li, Q; Li, T; Liu, X; Luo, Y; Mamo, M; McGonigal, TP; Mika, AK; Mitten, MJ; Nguyen, PT; Oleksijew, A; Oltersdorf, T; Powlas, JA; Rosenberg, SH; Shi, Y; Shoemaker, AR; Smith, RA; Stoll, VS; Thomas, SA; Woods, KW; Zinker, BA, 2005)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19904 (18.18)18.7374
1990's0 (0.00)18.2507
2000's3 (13.64)29.6817
2010's13 (59.09)24.3611
2020's2 (9.09)2.80

Authors

AuthorsStudies
Saghatchi, F1
Mohseni-Dargah, M1
Akbari-Birgani, S1
Saghatchi, S1
Kaboudin, B1
Sahu, R1
Mishra, R1
Kumar, R1
Majee, C1
Mazumder, A1
Kumar, A1
Mizojiri, R1
Nii, N1
Asano, M1
Sasaki, M1
Satoh, Y1
Yamamoto, Y1
Sumi, H1
Maezaki, H1
Zhang, D1
Zhang, X1
Ai, J1
Zhai, Y1
Liang, Z1
Wang, Y2
Chen, Y1
Li, C1
Zhao, F1
Jiang, H1
Geng, M1
Luo, C1
Liu, H1
Reddy, MR1
Reddy, PV1
Kumar, YP1
Srishailam, A1
Nambigari, N1
Satyanarayana, S2
Mishra, A1
Jeong, YJ1
Jo, JH1
Kang, SC1
Lah, MS1
Chi, KW1
Adhami, F1
Safavi, M1
Ehsani, M1
Ardestani, SK1
Emmerling, F1
Simyari, F1
Davari, AS1
Abnous, K1
Mehri, S1
Ghandadi, M1
Hadizadeh, F1
Mazuryk, O1
Suzenet, F1
Kieda, C1
Brindell, M1
Nagababu, P1
Barui, AK1
Thulasiram, B1
Devi, CS1
Patra, CR1
Sreedhar, B1
Gao, EJ1
Sun, TD1
Liu, SH1
Ma, S1
Wen, Z1
Zhu, MC1
Wang, L1
Gao, XN1
Guan, F1
Guo, MJ1
Liu, FC1
Tajima, H1
Honda, T1
Kawashima, K1
Sasabuchi, Y1
Yamamoto, M1
Ban, M1
Okamoto, K1
Inoue, K1
Inaba, T1
Takeno, Y1
Aono, H1
Roy, M1
Chakravarthi, BV1
Jayabaskaran, C1
Karande, AA1
Chakravarty, AR1
Kendall, JD2
O'Connor, PD1
Marshall, AJ1
Frédérick, R2
Marshall, ES2
Lill, CL2
Lee, WJ2
Kolekar, S2
Chao, M2
Malik, A2
Yu, S2
Chaussade, C2
Buchanan, C2
Rewcastle, GW2
Baguley, BC2
Flanagan, JU2
Jamieson, SM2
Denny, WA2
Shepherd, PR2
Giddens, AC1
Tsang, KY1
Singh, R1
KAPLAN, NO1
GOLDIN, A1
HUMPHREYS, SR1
CIOTTI, MM1
VENDITTI, JM1
BROMBACHER, PJ2
EMMELOT, P2
BECK, EG1
SANTER, A1
BROCKHAUS, A1
STOCK, CC1
BUCKLEY, S1
SUGIURA, K1
RHOADS, CP1
Luo, Y1
Shoemaker, AR1
Liu, X1
Woods, KW1
Thomas, SA1
de Jong, R1
Han, EK1
Li, T1
Stoll, VS1
Powlas, JA1
Oleksijew, A1
Mitten, MJ1
Shi, Y1
Guan, R1
McGonigal, TP1
Klinghofer, V1
Johnson, EF1
Leverson, JD1
Bouska, JJ1
Mamo, M1
Smith, RA1
Gramling-Evans, EE1
Zinker, BA1
Mika, AK1
Nguyen, PT1
Oltersdorf, T1
Rosenberg, SH1
Li, Q1
Giranda, VL1
Singh, P1
Kaur, P1
Luxami, V1
Kaur, S1
Kumar, S1

Reviews

2 reviews available for pyridine and Neoplasms

ArticleYear
Pyridine Moiety: An Insight into Recent Advances in the Treatment of Cancer.
    Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyridin

2022
Pyridine.
    IARC monographs on the evaluation of carcinogenic risks to humans, 2000, Volume: 77

    Topics: Animals; Carcinogenicity Tests; Carcinogens; Disease Models, Animal; Environmental Exposure; Female;

2000

Other Studies

20 other studies available for pyridine and Neoplasms

ArticleYear
Cancer Therapy and Imaging Through Functionalized Carbon Nanotubes Decorated with Magnetite and Gold Nanoparticles as a Multimodal Tool.
    Applied biochemistry and biotechnology, 2020, Volume: 191, Issue:3

    Topics: Contrast Media; Ferrosoferric Oxide; Gold; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging

2020
Design and synthesis of a novel 1H-pyrrolo[3,2-b]pyridine-3-carboxamide derivative as an orally available ACC1 inhibitor.
    Bioorganic & medicinal chemistry, 2019, 06-15, Volume: 27, Issue:12

    Topics: Acetyl-CoA Carboxylase; Administration, Oral; Amides; Animals; Drug Design; Enzyme Inhibitors; HCT11

2019
Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Bioorganic & medicinal chemistry, 2013, Nov-01, Volume: 21, Issue:21

    Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Moveme

2013
Synthesis, characterization, DNA binding, light switch "on and off", docking studies and cytotoxicity, of ruthenium(II) and cobalt(III) polypyridyl complexes.
    Journal of fluorescence, 2014, Volume: 24, Issue:3

    Topics: Anti-Bacterial Agents; Bacteria; Cell Survival; Cobalt; DNA; Intercalating Agents; Light; Magnetic R

2014
Anticancer potency studies of coordination driven self-assembled arene–Ru-based metalla-bowls.
    Chembiochem : a European journal of chemical biology, 2014, Mar-21, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cymenes; Gene Exp

2014
Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes.
    Dalton transactions (Cambridge, England : 2003), 2014, Jun-07, Volume: 43, Issue:21

    Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Coordination Complexes; Copper;

2014
Synthesis and biological evaluation of novel pyridine derivatives as potential anticancer agents and phosphodiesterase-3 inhibitors.
    Bioorganic chemistry, 2014, Volume: 57

    Topics: Antineoplastic Agents; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Phosphodiesterase 3 Inhibitors; P

2014
The biological effect of the nitroimidazole derivative of a polypyridyl ruthenium complex on cancer and endothelial cells.
    Metallomics : integrated biometal science, 2015, Volume: 7, Issue:3

    Topics: Animals; Apoptosis; Cell Adhesion; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cisplatin;

2015
Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers.
    Journal of medicinal chemistry, 2015, Jul-09, Volume: 58, Issue:13

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; C

2015
Synthesis, characterization, interaction with DNA and cytotoxicity in vitro of novel pyridine complexes with Zn(II).
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:10

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Crystallography, X-R

2010
Pyridylmethylthio derivatives as VEGF inhibitors. Part 1.
    Bioorganic & medicinal chemistry letters, 2010, Dec-15, Volume: 20, Issue:24

    Topics: Anilides; Animals; Arthritis, Experimental; Cell Line; Choroidal Neovascularization; Disease Models,

2010
Impact of metal binding on the antitumor activity and cellular imaging of a metal chelator cationic imidazopyridine derivative.
    Dalton transactions (Cambridge, England : 2003), 2011, May-14, Volume: 40, Issue:18

    Topics: Antineoplastic Agents; Apoptosis; Cations; Cell Line, Tumor; Chelating Agents; DNA Cleavage; Fluores

2011
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors.
    Bioorganic & medicinal chemistry, 2012, Jan-01, Volume: 20, Issue:1

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Binding Sites; Cell Li

2012
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR.
    Bioorganic & medicinal chemistry, 2012, Jan-01, Volume: 20, Issue:1

    Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Binding Sites; Cell Li

2012
Significance of enzymatically catalyzed exchange reactions in chemotherapy.
    Science (New York, N.Y.), 1954, Sep-17, Volume: 120, Issue:3116

    Topics: Animals; Coenzymes; Liver; Mice; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Pyridines; Tryptop

1954
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
    Biochimica et biophysica acta, 1956, Volume: 22, Issue:3

    Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA

1956
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
    Biochimica et biophysica acta, 1956, Volume: 22, Issue:3

    Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA

1956
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
    Biochimica et biophysica acta, 1956, Volume: 22, Issue:3

    Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA

1956
Enzymic activities of tumour mitochondria; pyridine nucleosidases and amination processes.
    Biochimica et biophysica acta, 1956, Volume: 22, Issue:3

    Topics: Amination; DNA; Humans; Mitochondria; N-Glycosyl Hydrolases; Neoplasms; Pyridines; RNA

1956
[BIOCHEMICAL STUDY OF THE EFFECT OF THE CYTOSTATIC QUARTZ ACTION THROUGH 3 LOW-MOLECULAR PYRIDINE-N-OXIDE COMPOUNDS ON AN ESTABLISHED CELL STRAIN (L929)].
    Zeitschrift fur Naturforschung. Teil B, Chemie, Biochemie, Biophysik, Biologie und verwandte Gebiete, 1964, Volume: 19

    Topics: Antineoplastic Agents; Cytostatic Agents; Neoplasms; Neoplasms, Experimental; Nitrous Oxide; Pyridin

1964
A comparison of the retardation of Sarcoma 180 by SK 1424, 3-Bis (beta-chloroethyl) aminomethyl-4-methoxymethyl-5-hydroxy-6-methyl-pyridine with that by HN2, Methylbis (beta-chloroethyl) amine.
    Cancer research, 1951, Volume: 11, Issue:6

    Topics: Amines; Animals; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Pyridines; Sarcoma; Sarcoma

1951
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:6

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Progression; Humans; Indazoles; Indoles; M

2005
Syntheses and anti-cancer activities of 2-[1-(indol-3-yl-/pyrimidin-5-yl-/pyridine-2-yl-/quinolin-2-yl)-but-3-enylamino]-2-phenyl-ethanols.
    Bioorganic & medicinal chemistry, 2007, Mar-15, Volume: 15, Issue:6

    Topics: Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Indoles; Molecu

2007